NCT06677307View on ClinicalTrials.gov

A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 13, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Alpha-1 Anti-trypsin DeficiencyAATD
Interventions
DRUG

KRRO-110

KRRO-110 drug product, IV

Trial Locations (4)

3004

RECRUITING

Nucleus Network Pty Ltd, Melbourne

3065

RECRUITING

St. Vincent's Hospital Melbourne, Melbourne

Unknown

NOT_YET_RECRUITING

New Zealand Clinical Research, Auckland

NOT_YET_RECRUITING

New Zealand Clinical Research, Christchurch

Sponsors

Lead Sponsor

Korro Bio, Inc.
All Listed Sponsors
lead

Korro Bio, Inc.

INDUSTRY

NCT06677307 - A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 | Biotech Hunter | Biotech Hunter